Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for Attendees of the Advanced Cell Therapy Summit in Shanghai

SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, will provide a Company cancer immunotherapy pipeline update and host a tour of its GMP facility for attendees of the Advanced Cell Therapy Summit 2018 in Shanghai on Monday, October 29, 2018. CBMG will host international attendees of the Summit comprised of key opinion leaders, investment and industry executives to tour its flagship GMP facility in Shanghai, and the Company’s Chief Executive Officer and Chief Scientific Officer will present an update on its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors, including:

  • CAR-T technology based B-cell maturation antigen (“BCMA”) specific cell therapy for multiple myeloma (“MM”), CD22 specific cell therapy for hairy cell leukemia (“HCL”) and anti-CD19 CAR-T relapsing acute lymphoblastic leukemia (“ALL”), CD20 specific cell therapy for anti-CD19 CAR-T relapsing non-Hodgkin’s lymphoma (“NHL”), and NKG2D specific cell therapy for acute myeloid leukemia (“AML”);  and
  • T-cell receptor (“TCR”) technology based AFP specific redirected T cell therapy for hepatocellular carcinoma (“HCC”); and
  • Neoantigen activated tumor infiltrating lymphocyte (“TIL”) technology based cell therapy for non-small cell lung cancer (“NSCLC”) and other solid tumors.  

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  Our Shanghai facility includes a ”Joint Laboratory of Cell Therapy” with GE Healthcare and a “Joint Cell Therapy Technology Innovation and Application Center” with Thermo Fisher Scientific, whose partnerships focus on improving manufacturing processes for cell therapies. The CBMG pipeline includes preclinical compounds targeting CD20-, CD22- and B-cell maturation antigen (BCMA)-specific CAR-T compounds, and T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) technologies. A Phase IIb trial in China for Rejoin®  autologous Human Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial in China for AlloJoin™ (CBMG’s “Off-the-Shelf” haMPC) for the treatment of KOA are ongoing. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, including regulatory approval of our IND applications, our plan to configure part of our Shanghai facility with GE Healthcare’s FlexFactory platform, our ability to execute on our obligations under the terms of our licensing and collaboration arrangement with Novartis, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law. 

Sarah Kelly 
Director of Corporate Communications, CBMG

+1 408-973-7884